Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 7:36 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 1,228 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: TBL 12 Clear all
Not listed Phase 1 Interventional Accepts healthy volunteers

A Study of Multiple-ascending Doses of GSBR-1290 in Healthy Overweight/Obese Participants

NCT06139055
View directory record Official record
Conditions
Healthy Volunteers
Interventions
GSBR-1290 (Capsule/Tablet), GSBR-1290, Placebo, Placebo (Capsule/Tablet)
Drug
Lead sponsor
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
3
States / cities
Miami, Florida • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 15, 2024 · Synced Nov 3, 2026, 7:36 AM EST
Terminated Phase 2 Interventional Results available

A Phase 2, Multi-Center Study To Compare The Efficacy And Safety Of A Chemokine CCR2/5 Receptor Antagonist With Ranibizumab In Adults With Diabetic Macular Edema

NCT01994291
View directory record Official record
Conditions
Macular Edema, Diabetic
Interventions
Ranibizumab, Placebo, PF-04634817, Masked Sham Therapy
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
33
States / cities
Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2016 · Synced Nov 3, 2026, 7:36 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Open-Label Study to Evaluate the Safety, Tolerability, and PK of Aramchol in Subjects With Hepatic Impairment

NCT04480827
View directory record Official record
Conditions
Hepatic Impairment
Interventions
Aramchol free acid tablet 600mg, single dose, Aramchol free acid tablet 300mg, bid
Drug
Lead sponsor
Galmed Research and Development, Ltd.
Industry
Eligibility
18 Years to 79 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 14, 2024 · Synced Nov 3, 2026, 7:36 AM EST
Recruiting Phase 1 Interventional Accepts healthy volunteers

Hepatic Impairment With Cirrhosis Due to Cholestatic Liver Disease

NCT05045482
View directory record Official record
Conditions
Hepatic Impairment, Cirrhosis, Cholestatic Liver Disease
Interventions
Saroglitazar Magnesium 1 mg, Saroglitazar Magnesium 2 mg
Drug
Lead sponsor
Zydus Therapeutics Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Nov 3, 2026, 7:36 AM EST
Completed Phase 3 Interventional Results available

A Double-blind, Placebo-controlled Study of the Safety and Efficacy of Paliperidone Extended Release (ER) in the Treatment of Schizophrenia in Adolescent Patients

NCT00518323
View directory record Official record
Conditions
Schizophrenia
Interventions
Paliperidone ER, Placebo
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
12 Years to 17 Years
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
10
States / cities
Cerritos, California • Fountain Valley, California • San Diego, California + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2014 · Synced Nov 3, 2026, 7:36 AM EST
Completed Phase 2 Interventional Results available

Sulforaphane for the Treatment of Young Men With Autism Spectrum Disorder

NCT02909959
View directory record Official record
Conditions
Autism Spectrum Disorder, Autistic Disorder, Neurodevelopmental Disorder, Childhood Developmental Disorders, Pervasive
Interventions
Sulforaphane, Placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
13 Years to 30 Years · Male only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Carrboro, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 4, 2020 · Synced Nov 3, 2026, 7:36 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Single Ascending Dose Study to Characterize the Pharmacokinetics, Safety, and Tolerability of SAR441566 in Healthy Adult Japanese Male Participants.

NCT05858788
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
SAR441566
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Nov 3, 2026, 7:36 AM EST
Terminated Phase 2 Interventional

Statin Monotherapy for Treatment of Endocrine Metabolic Disease Risk

NCT03113994
View directory record Official record
Conditions
Spinal Cord Injuries, Osteoporosis, Metabolic Syndrome
Interventions
Rosuvastatin Calcium, Placebo Oral Tablet, Coenzyme Q10, Calcium Carbonate, Vitamin D
Drug · Dietary Supplement
Lead sponsor
Dr. B. Catharine. Craven
Other
Eligibility
18 Years to 60 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Nov 3, 2026, 7:36 AM EST
Completed Phase 4 Interventional Results available

Effect of Ranolazine on Myocardial Perfusion Assessed by Serial Quantitative Exercise SPECT Imaging

NCT01221272
View directory record Official record
Conditions
Myocardial Perfusion Imaging, Myocardial Ischemia
Interventions
Ranolazine, Placebo to match ranolazine, SPECT MPI, Exercise
Drug · Procedure · Behavioral
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
26
States / cities
Birmingham, Alabama • Imperial, California • Lincoln, California + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2014 · Synced Nov 3, 2026, 7:36 AM EST
Completed Not applicable Interventional Results available

FGF-23 (Fibroblast Growth Factor 23) Regulation in Chronic Kidney Disease

NCT00999037
View directory record Official record
Conditions
Secondary Hyperparathyroidism
Interventions
Sevelamer Carbonate, Placebo
Drug · Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
6 Years to 21 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 31, 2023 · Synced Nov 3, 2026, 7:36 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Fixed Dose Combination of Macitentan/Tadalafil (10 mg/20 mg) Compared to the Reference Free Combination of Macitentan and Tadalafil in Healthy Adult Participants

NCT05236231
View directory record Official record
Conditions
Healthy
Interventions
Macitentan 10 mg, Tadalafil 20 mg, Macitentan 10 mg/Tadalafil 20mg FDC
Drug
Lead sponsor
Actelion
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 30, 2025 · Synced Nov 3, 2026, 7:36 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-Drug Interaction Study of VX-770 and VX-809 in Healthy Subjects

NCT01216046
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VX-809, VX-770, VX-809 placebo, VX-770 placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 18, 2012 · Synced Nov 3, 2026, 7:36 AM EST
Completed Phase 2 Interventional Results available

A Study to Investigate the Safety and Efficacy of ABBV-105 Alone or in Combination With Upadacitinib (ABBV-599 Combination) in Participants With Active Rheumatoid Arthritis

NCT03682705
View directory record Official record
Conditions
Rheumatoid Arthritis (RA)
Interventions
Elsubrutinib, Upadacitinib, Placebo for elsubrutinib, Placebo for upadacitinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
78
States / cities
Huntsville, Alabama • Mesa, Arizona • Peoria, Arizona + 66 more
Source: ClinicalTrials.gov public record
Updated May 3, 2021 · Synced Nov 3, 2026, 7:36 AM EST
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Chronic Hepatitis C Virus Infection Without Cirrhosis

NCT02114177
View directory record Official record
Conditions
Hepatitis C Virus Infection
Interventions
Simeprevir, Sofosbuvir
Drug
Lead sponsor
Janssen Infectious Diseases BVBA
Industry
Eligibility
18 Years to 70 Years
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
38
States / cities
Dothan, Alabama • Bakersfield, California • Chula Vista, California + 35 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2016 · Synced Nov 3, 2026, 7:36 AM EST
Completed Phase 3 Interventional Accepts healthy volunteers

Bioavailability and Bioequivalence Study of Extended Release Torsemide and Spironolactone

NCT07046975
View directory record Official record
Conditions
Bioavailability Heathy Volunteers
Interventions
Torsemide and Spironolactone tablet, Torsemide Tablets and Spironolactone Tablets
Drug
Lead sponsor
Sarfez Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Vienna, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Nov 3, 2026, 7:36 AM EST
Completed Phase 3 Interventional Results available

This Was a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder

NCT01972841
View directory record Official record
Conditions
Urinary Bladder Overactive, Urinary Bladder Diseases\Urologic Diseases, Overactive Bladder, Urgency Incontinence
Interventions
Solifenacin succinate, Mirabegron, Placebo to match solifenacin succinate, Placebo to match mirabegron
Drug
Lead sponsor
Astellas Pharma Europe B.V.
Industry
Eligibility
18 Years and older
Enrollment
3,527 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
121
States / cities
Mobile, Alabama • Chandler, Arizona • Phoenix, Arizona + 96 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2024 · Synced Nov 3, 2026, 7:36 AM EST
Active, not recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Treatment of Orthostatic Intolerance

NCT00262470
View directory record Official record
Conditions
Tachycardia, Chronic Orthostatic Intolerance
Interventions
Acetazolamide, Atomoxetine, NO Drug, Clonidine, Entacapone, Entacapone & Propranolol, Atomoxetine & Propranolol, Indomethacin, Mecamylamine, Isosorbide Dinitrate, Melatonin, Midodrine, Modafinil, Octreotide, Placebo, Propranolol, Modafinil & Propranolol, Sertraline, IV Saline, Drinking Water, Breathing Device, memantine, Abdominal binder
Drug · Other · Dietary Supplement + 3 more
Lead sponsor
Satish R. Raj
Other
Eligibility
18 Years to 70 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1997 – 2029
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Nov 3, 2026, 7:36 AM EST
Recruiting Not applicable Interventional

Tele-PCIT for Healthy Relationships in Families At-Risk

NCT07225010
View directory record Official record
Conditions
Disruptive Behavior, Pediatrics
Interventions
Telehealth Parent Child Interaction Therapy, Telehealth Parent Child Interaction Therapy (Delayed Start)
Behavioral
Lead sponsor
Medical University of South Carolina
Other
Eligibility
2 Years to 7 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Mar 6, 2026 · Synced Nov 3, 2026, 7:36 AM EST
Completed Phase 3 Interventional Results available

Pharmacologic Treatment of PTSD in Sexually Abused Children

NCT00078767
View directory record Official record
Conditions
Stress Disorders, Post-Traumatic
Interventions
Trauma-Focused Cognitive Behavioral Therapy, Sertraline Pill, Placebo Oral Tablet
Behavioral · Drug
Lead sponsor
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Other
Eligibility
10 Years to 17 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 5, 2017 · Synced Nov 3, 2026, 7:36 AM EST
Completed Phase 1 Interventional

Augmenting Zyprexa With Naltrexone to Ameliorate Metabolic Side-Effects

NCT00567034
View directory record Official record
Conditions
Schizophrenia, Psychotic Disorders
Interventions
naltrexone, placebo
Drug
Lead sponsor
Mclean Hospital
Other
Eligibility
21 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 25, 2013 · Synced Nov 3, 2026, 7:36 AM EST
Completed Phase 4 Interventional Results available

The Effectiveness And Safety Of Donepezil Hydrochloride (E2020) In Subjects With Mild To Severe Alzheimer's Disease Residing In An Assisted Living Facility

NCT00571064
View directory record Official record
Conditions
Mild to Severe Alzheimer's Disease
Interventions
Donepezil HCl
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
50 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
36
States / cities
Birmingham, Alabama • Phoenix, Arizona • Anaheim, California + 30 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2018 · Synced Nov 3, 2026, 7:36 AM EST
Completed Phase 2 Interventional

A Study to Evaluate SAR441566 Efficacy and Safety in Adults With Rheumatoid Arthritis

NCT06073093
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
SAR441566, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
17
States / cities
Northridge, California • Upland, California • Jacksonville, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2025 · Synced Nov 3, 2026, 7:36 AM EST
Withdrawn Phase 4 Interventional

A Crossover Study of Patients With HF to Compare Natriuretic Effects of IR Torsemide vs. ER Torsemide Over 12 Hrs

NCT06708611
View directory record Official record
Conditions
Heart Failure
Interventions
torsemide
Drug
Lead sponsor
Sarfez Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Nov 3, 2026, 7:36 AM EST
Completed Phase 2Phase 3 Interventional Results available

Study of Tadalafil Once-a Day for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia

NCT00384930
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
tadalafil, placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
45 Years and older · Male only
Enrollment
1,058 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Greenwood, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 2, 2009 · Synced Nov 3, 2026, 7:36 AM EST